Results 71 to 80 of about 923,769 (294)

Indicators of Innovation in Canadian Natural Resource Industries [PDF]

This report develops a set of indicators of innovation in a number of the natural resource industries in Canada. It then uses these indicators to assess trends in innovation over time in these industries.
Andrew Sharpe, Olivier Guibaud
core  

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

The challenge of measuring innovation types: A systematic literature review

Journal of Innovation & Knowledge
Measuring innovation has long posed a significant challenge and has been the subject of extensive scientific research. Various definitions and measures of innovation exist, and each measurement approach faces limitations.
Alina Stundziene, Vaida Pilinkiene, Mantas Vilkas, Andrius Grybauskas, Mantas Lukauskas   +4 more
doaj   +1 more source

Advanced materials foresight: research and innovation indicators related to advanced and smart nanomaterials. [PDF]

F1000Res, 2022
Farcal L, Munoz Pineiro A, Riego Sintes J, Rauscher H, Rasmussen K.   +4 more
europepmc   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Differentiation of innovation ecosystems of the countries being the Global Innovation Index leaders in the global competitive context [PDF]

Problems and Perspectives in Management
Innovations have become pivotal for the growth and competitiveness of national economies. Generating innovations necessitates a comprehensive ecosystem as a set of conducive conditions.
Maxim Polyakov, Igor Khanin, Vladimir Bilozubenko, Gennadij Shevchenko, Maxim Korneyev   +4 more
doaj   +1 more source

Innovation indicators based on firm websites-Which website characteristics predict firm-level innovation activity? [PDF]

PLoS One, 2021
Axenbeck J, Breithaupt P.
europepmc   +1 more source

Outputs of innovation systems: a European perspective [PDF]

This paper focuses upon the performance of innovation systems from an output perspective. On it, we try to characterize some European countries according to seven innovation output indicators in the manufacturing and service sectors.
Edquist, Charles, Zabala, Jon Mikel
core  

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source